Teleflex's Stock Buy Rating: Diverse Portfolio and Strategic Market Advantages Propel Growth
Teleflex Price Target Maintained With a $260.00/Share by RBC Capital
Teleflex Analyst Ratings
RBC Capital Maintains Teleflex(TFX.US) With Buy Rating, Maintains Target Price $260
RBC Capital Remains a Buy on Teleflex (TFX)
Truist Securities Maintains Hold on Teleflex, Raises Price Target to $247
Truist Financial Maintains Teleflex(TFX.US) With Hold Rating, Announces Target Price $247
U.S. Stock Market Dynamics: Teleflex rose more than 8% in pre-market trading, and many major banks raised its target price.
Teleflex Price Target Raised to $260.00/Share From $235.00 by RBC Capital
Teleflex Analyst Ratings
BofA Securities Maintains Teleflex(TFX.US) With Hold Rating
Needham Maintains Teleflex(TFX.US) With Hold Rating
A Quick Look at Today's Ratings for Teleflex(TFX.US), With a Forecast Between $243 to $290
RBC Capital Keeps Their Buy Rating on Teleflex (TFX)
Teleflex Holds Steady: Solid Performance With Moderate Growth Outlook Despite Headwinds
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX) and Teleflex (TFX)
Buy Rating Affirmed for Teleflex on Strong Performance and Promising Outlook
Wells Fargo Raises Teleflex's Price Target to $243 From $210
Teleflex Poised for Growth: Strong Q2 Performance and Strategic Initiatives Validate Buy Rating
Teleflex's Barrigel Poised for Growth in Prostate Therapy Market, Yet Holds Steady Amid Balanced Expectations